Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington’s Disease

Federica Cesca1, Elisa Bregant2, Borut Peterlin3, Maja Zadel3,4, Giorgia Dubsky de Wittenau1, Gabriele Siciliano5, Roberto Ceravolo6, Lucia Petrozzi2, Giada Pauletto6, Lorenzo Verriello6, Paolo Bergonzi6, Giuseppe Damante2, Giovanni Barillari7, Brunoucci8, Francesco Curcio1,9, Incoronata Renata Lonigro1,9

1 Dipartimento di Scienze Mediche e Biologiche, Università degli Studi di Udine, Udine, Italy, 2 SOC Istituto di Genetica, Azienda Ospedaliero Universitaria di Udine, Udine, Italy, 3 Clinical Institute of Medical Genetics, University Medical Centre, Ljubljana, Slovenia, 4 Community Health Centre Ljubljana, Metelkova, Ljubljana, Slovenia, 5 Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Pisa, Pisa, Italy, 6 Clinica Neurologica Azienda Ospedaliero Universitaria di Udine, Udine, Italy, 7 Medicina Trasfusionale, Azienda Ospedaliero Universitaria di Udine, Udine, Italy, 8 Neurologia, Azienda Ospedaliera, Santa Maria degli Angeli, Pordenone, Italy, 9 SOC Istituto di Patologia Clinica, Azienda Ospedaliero Universitaria di Udine, Udine, Italy

* renata.lonigro@uniud.it

Abstract

Abnormalities of intracellular Ca2+ homeostasis and signalling as well as the down-regulation of neurotrophic factors in several areas of the central nervous system and in peripheral tissues are hallmarks of Huntington’s disease (HD). As there is no therapy for this hereditary, neurodegenerative fatal disease, further effort should be made to slow the progression of neurodegeneration in patients through the definition of early therapeutic interventions. For this purpose, molecular biomarker(s) for monitoring disease onset and/or progression and response to treatment need to be identified. In the attempt to contribute to the research of peripheral candidate biomarkers in HD, we adopted a multiplex real-time PCR approach to analyse the mRNA level of targeted genes involved in the control of cellular calcium homeostasis and in neuroprotection. For this purpose we recruited a total of 110 subjects possessing the HD mutation at different clinical stages of the disease and 54 sex- and age-matched controls. This study provides evidence of reduced transcript levels of sarco-endoplasmic reticulum-associated ATP2A2 calcium pump (SERCA2) and vascular endothelial growth factor (VEGF) in peripheral blood mononuclear cells (PBMCs) of manifest and pre-manifest HD subjects. Our results provide a potentially new candidate molecular biomarker for monitoring the progression of this disease and contribute to understanding some early events that might have a role in triggering cellular dysfunctions in HD.
Introduction

Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder involving brain and systemic alterations. The disease is characterized, among others, by the progressive loss of striatal medium spiny neurons, with an onset of symptoms at a mean age of 45 years. Progressive motor and cognitive decline and the development of psychiatric symptoms [1,2] are well known signs of the disease. HD is caused by the expansion of a polyglutamine stretch in the huntingtin (HTT) protein [3]. Mutant huntingtin (mHTT) gains toxic function [4–15], primarily in medium spiny neurons (MSNs) [16], with aberrant interactions in several pathways, including gene expression, oxidative stress, mitochondrial function, energy metabolism, Ca²⁺ homeostasis and signalling. mHTT is ubiquitously expressed and there is growing evidence that the mutant protein causes cytotoxicity not only in the central nervous system but also in the peripheral tissue of patients with HD [17]. Unfortunately, there is no known cure for this disease. To plan an early and effective therapeutic intervention, it is necessary to know the molecular mechanisms that trigger cellular dysfunction in HD, even in the period preceding the onset of symptoms. Furthermore, molecular biomarker(s) for the monitoring of disease onset and/or progression and response to treatment, need to be identified. However, the non-invasive detection of clinically useful biomarkers is a challenge faced by many research laboratories in the last few years. Multiple alterations in gene expression patterns, mainly using microarray technology and the further validation of selected genes, have been shown in the peripheral tissues of HD patients and in the peripheral blood of mouse models of HD [17–24]. For instance, variation in the expression level of genes involved in energy metabolism, oxidative stress and inflammatory response in peripheral leukocytes of HD patients with respect to control individuals have been reported [21–23]. Different studies have suggested that the toxic mHTT gain of function may involve disturbed glutamate-induced Ca²⁺ signalling in MSNs [9,25]. It has been reported that mHTT facilitates the activity of NMDA receptors [15,26–30] and type 1 inositol 1,4,5-triphosphate receptors (InsP₃R1) [31,32], leading to enhanced intracellular Ca²⁺ concentrations in HD neurons. Furthermore, in peripheral tissues altered RNA expression of genes linked to Ca²⁺ homeostasis in HD patients with respect to controls has been reported (17). In spite of the fact that one of the hallmarks of HD is an impairment of the intracellular Ca²⁺ concentration and signalling, only recently the expression of genes encoding the calcium signalosome has been investigated in cellular and transgenic models of HD [33]. In this paper the authors describe changes in the gene expression of members of the calcium signalosome. However, these changes differ in the two models of HD used in the study. To date, the gene expression of calcium pumps dedicated to the extrusion of calcium from the cytoplasm (PMCA1-4 isoforms) or its storage in the cisterns of the endoplasmic reticulum (SERCA pumps) has not yet been directly explored. In this work, we investigated the mRNA levels of both the housekeeping-expressed plasma membrane-associated PMCA1 isoform [34–35] and the sarco-endoplasmic reticulum-associated (SERCA2 and SERCA3) pumps in PBMCs from manifest and pre-manifest HD patients compared to sex- and age-matched controls.

Furthermore, to date, the expression level of neurotrophic and neuroprotective agents as potential tracer(s) of disease onset and/or progression has not been sufficiently explored. Indeed, neurotrophic factors such as brain-derived neurotrophic factor, glial-derived neurotrophic factor and ciliary neurotrophic factor are transcriptionally deregulated in HD striatal neurons and have been found to be neuroprotective in a variety of animal models of HD [18–20,36,37]. Among others, vascular endothelial growth factor (VEGF) has neurotrophic and neuroprotective properties in addition to its well-known angiogenic functions. VEGF directly exerts neuroprotective actions, through the inhibition of programmed cell death or apoptosis and the stimulation of neurogenesis [38–45], as well as indirectly, by activating antioxidants,
promoting angiogenesis and enhancing blood brain barrier permeability for glucose [46–53]. Although VEGF acts as an endogenous neuroprotective factor, it is produced by both neuronal and non-neuronal cells, including endothelia and astroglia. VEGF released from these sources might target VEGF receptors on the surface of neurons [40] and contribute to their tropism and survival.

In this study, we also investigated the level of VEGF mRNA expression in PBMCs from the above-described cohort of HD and control subjects. Our results provide a potentially new molecular biomarker for monitoring the progression of the disease and shed new light on some early events that may contribute to cellular dysfunction in HD.

**Materials and Methods**

**Human ethics**
All samples were obtained in accordance with the institutional Bioethics Committee named “Comitato Etico dell’Azienda Ospedaliero-Universitaria Santa Maria della Misericordia”, which approved this study. The patients or their legal guardians gave written informed consent.

**Patients recruitment and samples collection**
All the patients and controls were residents of Italy and Slovenia. The HD group consisted of 90 HD manifest patients, of which 45 were male and 45 female (average age 54.1 ± 12.8 years), and 20 HD pre-manifest patients, 10 male and 10 female (average age 38.8 ± 8.4 years). The control group consisted of 54 healthy subjects (33 male and 22 female) matched for sex and age, who were recruited among blood donors and without a family history of HD. All samples were collected between 9:00 and 10:00 a.m. in fasting conditions and a sample (5 ml) of peripheral blood was collected in Vacutainer tubes with EDTA and processed with FicollPaque (GE Healthcare) according to the manufacturer’s instructions. Peripheral blood mononuclear cells (PBMCs) were collected.

**Clinical classification of patients**
All the subjects, patients and controls, were grouped arbitrary in three range of age (27–40; 43–58; 59–84 years old; range of CAG repeats 47–57, 49–56 and 37–49 respectively) in an attempt to account for aging-dependent variation of gene expression. Alternatively, where indicated, the HD patients enrolled in this study were stratified upon their neurological status. The Unified Huntington’s Disease Rating Scale (UHDRS) by an experienced HD neurologist has been used to determine neurological status. All of the manifest patients were in stages I or II of HD as determined by total functional capacity scores of 7–12. UHDRS total motor score (UHDRS-TMS) between 5 and 24 defined early-manifest patients, UHDRS-TMS between 25 and 50 defined manifest patients, and a score of more than 50 defined late-manifest HD patients. In summary, the 20 pre-manifest patients (mean age 40.9 ± 5.5 years), relatives of already manifest subjects, were carriers of the HD-causing mutation (range of CAG repeats 39–48) but still negative by clinical evaluation; the 17 early-manifest patients (mean age 47.9 ± 10.5; range of CAG repeats 40–52) experienced the onset of poor control of voluntary movements of the limbs and facial grimaces with or without psychic disorders; the 18 late-manifest patients (mean age 59.3 ± 11.9 years; range of CAG repeats 40–57) usually presented dementia as well as marked hyperkinesia or even severe spastic tetraplegia and mutism. The remaining 55 subjects (mean age 52.2 ± 11.1 years; range of CAG repeats 37–50) were grouped in the manifest category.
No patients had any medication suspected or known to interfere with the experimental methods used and/or with the gene expressions analysed.

**DNA extraction and molecular diagnosis of HD**

DNA was isolated using the *Purgene DNA Purification kit* (Gentra Systems) according to the manufacturer’s instructions. The DNA concentration was determined using the *Quantifluor dsDNA System* (Promega), and the DNA quality was determined on a 1% agarose gel (TBE 0.5 X) with GelRed (Biotium) using *Lambda DNA/HindIII* as a marker of molecular weight (Fermentas).

To evaluate the number of CAG repeats and to exclude false homozygous states that can be due to the occurrence of SNPs in the region of primer annealing, we performed three independent PCR reactions. Briefly, the primers HD1F and HD3R were used to amplify the CAG repeat, HD4 and HD5 were used to amplify the CCG repeat immediately downstream of the CAG region, and HD1 and HD5 were used to amplify the entire CAGCG region. The sequences of the primers and references are shown in Table 1. The protocol of the PCR reaction mix and cycles was optimized to be unique in getting separate amplics of the three repeated regions. Precisely, the PCR reactions were performed in a final volume of 25 μl containing 4 μl of each specific primer (5 pmol/μl), 2.5 μl of buffer 10X (Applied Biosystem), 7.5 μl glycerol 50%, 0.88 μl dimethyl-formamide, 1.0 μl dNTPs (5 mM), 0.38 μl AmpliTaq DNA polymerase (5 U/μl) (Applied Biosystems), 2 μl of genomic DNA (100 ng/μl) previously denaturated at 95°C for 7 min and water to 25 μl. The amplification was performed with an initial denaturation at 94°C for 1 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 66°C for 30 sec and elongation at 72°C for 30 sec and a final extension at 72°C for 7 min. The PCR fragments were resolved by capillary electrophoresis on an automated ABI Prim 3730 XL Genetic Analyzer in presence of HiDi formamide and Gene Scan 500-LIZ 500 internal size standard (Applied Biosystems). The data were analysed using Peak Scanner Software (Life Technologies).

**RNA preparation and reverse transcription**

Total RNA from PBMCs was extracted with *RNeasy Mini Kit* (Qiagen) according to the manufacturer’s instructions, and 450 ng of total RNA was reverse-transcribed using *SuperScript III Reverse Transcriptase* (Life Technologies) and random hexaprimers (Invitrogen), according to the manufacturer’s instructions. Three independent reactions were performed for each RNA sample to correct for inter-assay variability. Briefly, the RNA plus random hexaprimers was rapidly denatured at 65°C for 5 min, and the RT-PCR protocol was carried out as follows: 55°C for 60 min, 70°C for 15 min and 95°C for 5 min, followed by cooling at 4°C. The three RT-PCR products, relative to each RNA sample, were pooled and used in three independent real-time PCR assays.

| Name | Sequence | Length | Amplified Region | Reference |
|------|----------|--------|------------------|-----------|
| HD1F | ATGAAGGCCTTCGAGTCCCTAAAGTCCTTC | 30 bp | CAG | [54] |
| HD3R | GGCCTGAGGCGGTGGCTGCTGCTGCTGCTGC | 30 bp | | |
| HD4F | GCAGCAGCAGCAACAGCGCCCGCCACCGCC | 30 bp | CCG | [55] |
| HD5R | GCCTGGCTGAGGAGCTGAG | 21 bp | | |

Table 1. Primers used to evaluate the number of CAG repeats for the molecular diagnosis of HD.

DOI:10.1371/journal.pone.0125259.t001
Relative RNA quantification

For the detection and relative quantification of target gene transcripts, TAQMan gene expression assays (Applied Biosystems) and a 7500 Real-Time PCR System (Applied Biosystems) were used. β-actin was used as the reference gene. Each target and reference gene were co-amplified in the same reaction tube to minimise variability. The list of human assays for target genes is shown in Table 2. The sequences of the primers and probe used for β-actin are reported in Table 3. Probes specific for the target genes were labelled with the FAM fluorophore, and the β-actin probe was labelled with the VIC fluorophore. Each duplex real-time PCR contained 6.5 μl of 2X MasterMix (Applied Biosystems), 0.3 μl of gene-specific TAQMan gene expression assay, 0.55 μl of β-actin forward primer (10 μM), 0.55 μl of β-actin reverse primer (10 μM), 0.125 μl of β-actin probe (10 μM), 0.5 μl 50 mM MgCl₂, 2 μl cDNA template and water to 12.5 μl. In all the assays the gene expression levels detected in the samples tested have been reported to the gene expression levels detected in the ARO cell line that was used as an internal calibrator sample.

Data processing and statistical analysis

Experimental data from real-time PCR were reported as threshold cycle (Ct) values and summarized as mean ± SD of three independent experiments, as indicated in the figure legends. Each experiment was performed on individual samples in triplicate. Ct values for each gene were normalized to internal control (β-actin) that was run with each tested sample. Differences in gene expression were calculated using the ΔΔCt method, as previously described [56]. The significance of expression differences between tested groups was calculated using a two-tailed unpaired Student’s t-test, for the comparison of two means, by the QuickCalcs on-line software (www.graphpad.com) and p values <0.05 were considered to be significant. Linear regression analysis was employed to assess correlation between number of CAG repeats and gene expression levels.

Results

Probing RNA level of PMCA1, SERCA2, SERCA3 and VEGF in peripheral blood of a limited cohort of HD patients and controls

To address the steady-state level of PMCA1, SERCA2-3 and VEGF transcripts in the peripheral blood of HD patients and controls, RNA was extracted from PBMCs of 20 HD subjects (10

Table 2. List of genes assessed for their expression level using multiplex real-time PCR assays and annotation.

| Gene name/symbol | Description | Applied Biosystems assay ID |
|------------------|-------------|-----------------------------|
| ATP2B1/PMCA1     | ATPase, Ca++ transporting, plasma membrane 1 | Hs00155949_m1 |
| ATP2A3/SERCA3    | ATPase, Ca++ transporting, ubiquitous      | Hs00193090_m1 |
| ATP2A2/SERCA2    | ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 | Hs00544877_m1 |
| VEGF             | Vascular endothelial growth factor A        | Hs00900054_m1 |

doi:10.1371/journal.pone.0125259.t002

Table 3. Primer and probe sequences used for the real-time detection of β-actin.

| Name              | Sequence                  | Length |
|-------------------|---------------------------|--------|
| β-actin 611 TAMRA probe | ACC ACC ACG GCC GAG CGG   | 18 bp  |
| β-actin-592F forward primer | CGA GCG CGG CTA CAG CTT  | 18 bp  |
| β-actin-651R reverse primer | TCC TTA ATG TCA CGC ACG ATT T | 22 bp  |

doi:10.1371/journal.pone.0125259.t003
males, with a mean age of 44.5 ± 10.1, and 10 females, with a mean age of 53.4 ± 9.6) and 20 age-matched (± 3 years) and sex-matched (10 males and 10 females) healthy controls. Each RNA was reverse transcribed in three independent reactions, and 2 μl of pooled cDNA was probed for the evaluation of the gene-specific expression level, as described in Materials and Methods. As shown in Fig 1, the mRNAs of PMCA1 and SERCA3 showed similar levels in the HD and control groups, both in the male and female subjects. In contrast, the levels of SERCA2 and VEGF mRNAs were significantly reduced in the HD patients (p < 0.005) compared to the age- and sex-matched controls. Because no sex-related differences were found regarding the mRNA level of the four genes tested, all further analyses were performed pooling the results obtained from males and females for both the HD and control subjects.

**The mRNA level of SERCA2 is reduced in HD manifest as well as pre-manifest subjects and has a negative correlation with the expansion of the CAG repeat**

The steady-state level of SERCA2 mRNA in PBMCs was analysed on a total of 164 subjects comprised of Italian and Slovenian individuals. In total, 90 HD manifest patients (45 males and 45 females), 20 pre-manifest carriers of HD causative mutation (10 males and 10 females) and 54 age- and sex-matched controls (33 males and 22 females) were analysed. Because SERCA2 gene expression has been reported to be reduced with ageing [57–59], the subjects analysed were subdivided in three arbitrary age ranges: 27–40, 43–58 and 59–84 years. No pre-manifest subjects were available in the 59–84 range of age. As shown in Fig 2A, all the HD-affected patients and even all the pre-manifest subjects displayed a highly significant reduction in SERCA2 mRNA, ranging from p < 0.01 and p < 0.001, compared with the control mRNA.
Fig 2. mRNA quantification of the SERCA2 pump relative to the age, clinical conditions and CAG expansion of the patients. (A) Comparison of the level of SERCA2 mRNA in PBMCs from HD pre-manifest and manifest patients and age- and sex-matched healthy controls. Age 27–40: Controls = 15; pre-manifest = 12; manifest = 13; Age 43–58: Controls = 26; pre-manifest = 8; manifest = 42; Age 59–84: Controls = 13; manifest = 35. ** p<0.01; *** p<0.001. (B) Comparison of the level of SERCA2 mRNA in PBMCs of patients with different stages of the disease: pre-manifest = 20; early-manifest = 17; manifest = 55; late-manifest = 18. (C) Correlation between the level of SERCA2 mRNA and the number of CAG repeats (range 37–46) R² = 0.9611. (D) Correlation between the level of SERCA2 mRNA and the number of CAG repeats (range 46–56) R² = 0.6793. The mean values ± SD of three independent assays are shown.

doi:10.1371/journal.pone.0125259.g002
levels. However, the reduction of SERCA2 mRNA in the manifest versus pre-manifest subjects did not reach statistical significance. Furthermore, as shown in Fig 2B, no progressive reduction of SERCA2 mRNA was observed when stratifying the patients according to their clinical phenotype, namely, pre-manifest (N = 20), early-manifest (N = 17), manifest (N = 55) and late-manifest (N = 18). This result suggests that the impairment in SERCA2 gene expression is not a biomarker of onset and progression of the disease, however it is a precocious sign of events underlying cellular dysfunction in HD. Interestingly, by plotting the SERCA2 mRNA level against the number of CAG repeats, in the range of 37 and 46 CAG (Fig 2C), a linear regression of \( R^2 = 0.9611 \) was observed. No further reduction in SERCA2 RNA was detected for the 25 HD subjects with CAG expansion greater than 46 repeats, from 47 up to 56 CAG (Fig 2D). In an attempt to ensure cell survival, some compensatory mechanisms may be activated when a higher CAG expansion is present. Conversely, specific molecular interactions, which may be responsible for the observed reduction in SERCA2 mRNA, may occur in the case of lower expansion (37–46 CAG repeats). Further investigation needs to be performed to understand the molecular mechanisms that inversely correlate SERCA2 mRNA expression and CAG repeats (i.e., 37–46). Some hypotheses on possible mechanisms underlying this observation will be discussed.

The mRNA level of VEGF is more reduced in HD manifest than in pre-manifest patients with respect to controls, and no correlation is evident with the expansion of the CAG repeat

The results obtained by analysing the steady-state levels of VEGF mRNA in the PBMCs of the same 164 subjects are shown in Fig 3A. As found for SERCA2 mRNA, the VEGF mRNA levels were also lower in all subjects carrying the mutation, both the pre-manifest (p < 0.01) and manifest (p < 0.001) subjects, when compared to the sex- and age-matched controls. Moreover, the mRNA level appeared to be inversely correlated with the onset and progression of the disease. Indeed, as shown in Fig 3B, by stratifying the patients according to their clinical phenotype, a significant reduction in VEGF mRNA (p < 0.05) was observed in the late-manifest compared to the early and pre-manifest patients. Although this observation needs to be refined through the analysis of a greater number of subjects, it suggests a potential role of VEGF as a candidate biomarker useful for tracing the progression of Huntington’s disease. No correlation was observed between the level of VEGF mRNA and the number of CAG repeats in any range analysed (data not shown).

Discussion

The identification of quantitative biomarkers of neurodegeneration that highlights the onset and/or progression of symptoms remains a priority for patient management and for developing effective therapies. Huntington’s disease remains an incurable and fatal disease due to a toxic gain of function by the HTT mutant protein. Recent evidences show that mHTT induces alterations in areas of the central nervous system as well as in the peripheral tissues of patients with HD. The availability of peripheral biomarkers for tracing the onset and/or progression of the disease represents a reasonable goal for the clinical management of HD patients. Within this context, the number of studies aiming to identify molecular alterations in the peripheral tissues of patients and/or animal models of HD is increasing. Different attempts to compare gene expression profiles of HD tissues and matched controls have been made using microarray technology. Borovecky et al. [18] performed a genome-wide expression profiling of human blood and showed, in pre-manifest and manifest HD subjects, a significant up-regulation of genes belonging to many different functional groups, such as transcription / RNA processing,
ubiquitin / proteasome, vesicle trafficking, and signal transduction, as compared to control groups. The up-regulation of twelve selected genes has been confirmed through qRT-PCR assays. However, these promising results were not reproduced by Runne and co-workers [19] on a different cohort of HD patients and controls. Nor other potential useful marker has been found by the peripheral transcriptomic analysis performed by these authors. This suggests that peripheral transcriptomics fails in providing common validated biomarkers in HD or rather emphasizes a need for further validations on new and enlarged cohorts of patients.

Fig 3. mRNA quantification of VEGF relative to the age and clinical conditions of the patients. (A) Comparison of the level of VEGF mRNA in PBMCs from HD pre-manifest, manifest patients and age- and sex-matched healthy controls. Age 27–40: Controls = 15; pre-manifest = 12; manifest = 13; Age 43–58: Controls = 26; pre-manifest = 8; manifest = 42; Age 59–84: Controls = 13; manifest = 35; ** p<0.01; *** p<0.001. (B) Comparison of the level of VEGF mRNA in PBMCs of patients with different stages of the disease: pre-manifest = 20; early-manifest = 17; manifest = 55; late-manifest = 18;* p<0.05. The mean values ± SD of three independent assays are shown.

doi:10.1371/journal.pone.0125259.g003
Furthermore, differences in array platforms sensitivity and probes design and/or qRT-PCR detection methods and reagents and/or samples preparation methods may account for differences reported in different studies on gene expression profile in blood. Recently, in the attempt to find a cell type alternative to blood cells for biomarker studies in HD, Marchina et al. (17) performed gene expression profiling analysis on skin fibroblasts of HD patients and controls. Interestingly, in a set of nine genes confirmed to be differentially expressed between HD and controls the phosphoinositide-specific phospholipase C β4 (PLCβ4) gene is strongly upregulated. PLCβ4 over-expression could be linked to the altered Ca2+ homeostasis in this cell type in HD. Deregulated Ca2+ homeostasis is a well-established hallmark of HD. Considering the harmful effects of increased levels of intracellular calcium, the expression and activity of pumps able to actively counteract the augment of Ca2+ concentration in HD neurons may play a key role in the onset and/or progression of the disease. Plasma membrane and sarco/endo-plasmic Ca2+ ATPases, namely PMCA and SERCA pumps, play a pivotal role in cellular calcium homeostasis and in regulating the physiological resting level of calcium [60–61]. In our study, we adopted a multiplex real-time PCR approach to compare the RNA levels of the housekeeping-expressed PMCA1 pump and the SERCA2 and SERCA3 pumps in PBMCs isolated from blood samples of patients with HD, pre-manifest subjects and sex- and age-matched healthy controls. Comparable levels of PMCA1 and SERCA3 mRNAs were found in all HD and control groups examined, whereas the SERCA2 mRNA level was significantly reduced in all the subjects carrying the HD causative mutation, both manifest and pre-manifest subjects. These results suggest that, at least in the cohort of patients we examined, the impairment of SERCA2 gene expression is an early pathogenetic event underlying peripheral cells dysfunction in HD. However, because no significant and progressive reduction was observed by comparing SERCA2 mRNA expression levels in PBMCs from pre-manifest, early-manifest and late-manifest patients, SERCA2 could be considered as a biomarker of the genetic status but not of the onset or progression of the disease.

It must be said that apparently, the reduction of SERCA2 mRNA level in blood of HD patient respect to controls is not confirmed by the work of Diamanti et al. (24) on mice models of HD. Indeed, in the arrays analysis conducted by these authors on peripheral blood of R6/2 mice in the symptomatic stage and wild type littermate mice, even if some of the gene set arrays contain SERCA2-specific probes no altered expression profile of SERCA2 mRNA has been reported in blood of HD with respect to control mice. A simple explanation of these conflicting results could be that the microarray assays have a different sensitivity than the QPCR assays. Alternatively, an intriguing explanation could arise from the observation that the R6/2 mice express a short fragment of mHTT but carrying a large poly-Q trait (about 110Q). None of the patients we examined have a similar number of polyQ in the mHTT. Furthermore, as shown in Fig 2C, we found a significant inverse correlation between the expanded poly-Q tract of mHTT and the SERCA2 mRNA level only in the range of 37Q-46Q-46QQ. Further expansions of poly-Q trait (47QQ-56Q) are not accompanied by a further reduction of SERCA2 mRNA level in blood, rather an opposite finding, though not significant in that group of patients, seems to exist with more than 46Q (Fig 2D). This observation suggests that peculiar molecular interaction(s) could link the mHTT protein and SERCA2 gene expression in a polyQ-dependent manner. One possible explanation of this could be that different conformational/functional properties are acquired by the mutant proteins with differently expanded polyQ traits, and this could affect a gene-specific expression. The first unveiled mechanism drawing transcriptional alterations in HD was a direct protein-protein interaction of mHTT with transcription factors. However, a more likely scenario has been depicted by Benn and co-workers [62] in demonstrating that the wild type and the mutant HTT both bind directly DNA, have different genomic binding sites in vivo, including different gene promoters and sites for transcription factor
occupancy. The mHTT could inhibit a proper binding of transcription factors to DNA and/or alter DNA conformation and hence alter the gene transcription. These findings suggest the need of a more detailed investigation of the gene expression patterns related to a defined expansion of the poly-Q tract in HD. This is reinforced by our finding showing the occurrence of a progressive reduction of SERCA2 mRNA level only in a defined range of the poly-Q dimension. Clarifying the peculiar molecular interaction(s) linking the mutant protein and SERCA2 gene expression could provide new insights in differential and early occurring molecular mechanisms that contribute to trigger cellular dysfunction in HD.

Another well-established hallmark of HD is the reduced expression of neurotrophic and neuroprotective agents. VEGF gene expression has also been found to be impaired in both manifest and pre-manifest patients, highlighting the need to improve the signalling of neuroprotective agents in HD. Interestingly, Ellison and co-workers recently exploited a lentiviral-mediated delivery of VEGF and 82Q mHTT in rat primary striatum cell cultures and in adult rat striatum, demonstrating a strictly dose-dependent neuroprotection exerted by the VEGF165 isoform in these models of HD [37]. In our study, the level of VEGF mRNA in PBMCs of HD mutation carriers was found to be inversely correlated with the progression of the disease. Indeed, when stratifying the patients according to their clinical phenotype, a significant reduction of VEGF mRNA was observed in blood of late manifest compared to early and pre-manifest patients. Although this observation needs to be confirmed through the analysis of a larger number of subjects and on different populations, it suggests a potential role of VEGF mRNA as a useful candidate biomarker for following up the progression of Huntington’s disease.

In conclusion, to the best of our knowledge, data reported here are the only directly addressing the Calcium pumps and VEGF mRNA levels in blood of HD. Certainly the work we have presented has several limitations such as to validate the results obtained on a different cohort of patients and investigate the possible pathogenetic significance of the reduction of SERCA2 and VEGF mRNAs both in peripheral tissues and the central nervous system of HD patients. Consistent with the above, the evaluation of SERCA2 and VEGF protein levels in the peripheral blood of patients and controls is missing. Nevertheless, the data presented are consistent with the aim of this work that is the search for biomarkers in peripheral blood of HD patients useful in monitoring the onset and / or progression of the disease. Our overall results suggest that the evaluation over time of VEGF mRNA level in blood of HD patients could be helpful in monitoring the progression of the disease. Moreover, the evaluation of VEGF and SERCA2 mRNAs both could be helpful in monitoring the response to therapy in clinical trials. Finally, the results of our study could provide new insight to understand early events that could contribute to cellular dysfunction in HD.

Acknowledgments
We thank the patients and relatives for their collaboration on this project as well as the healthy controls for their voluntary enrolment.

Author Contributions
Conceived and designed the experiments: F. Cesca IRL. Performed the experiments: F. Cesca EB GDdW. Analyzed the data: F. Cesca IRL. Contributed reagents/materials/analysis tools: BP MZ GS RC LP GP LV GB. Wrote the paper: F. Cesca IRL. Partial enrollment of patients: PB. Supervisor of project application fundings: BL. Paper revision and editing: GD F. Curcio.
References

1. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998; 57: 369–384. PMID: 9596408
2. MacDonald ME. Huntingtin: alive and well and working in middle management. Sci STKE 2003; pe48.
3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971–983. PMID: 8458085
4. Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000; 10: 531–536. PMID: 11121745
5. Ross CA. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002; 38: 425–433. PMID: 11121745
6. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci. 2003; 28: 425–433. PMID: 12932731
7. Trushina E, Heldebrant MP, Perez-Terzic CM, Bortolon R, Kovtun IV, Badger JD, et al. Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc Natl Acad Sci U S A 2003; 100: 12171–12176. PMID: 14527999
8. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003; 19: 233–238. PMID: 12711212
9. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004; 322: 1310–1317. PMID: 15336977
10. Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet. 2005; 37: 198–204. PMID: 15654337
11. Li S, Li XJ. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener. 2006; 1: 19. PMID: 17173700
12. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1 alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59–69. PMID: 17018277
13. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007; 145: 1233–1248. PMID: 17303344
14. Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007; 81: 272–293. PMID: 17188796
15. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009; 29: 3200–3205. doi: 10.1523/JNEUROSCI.5599-08.2009 PMID: 19279257
16. Roze E, Cahill E, Martin E, Bonnet C, Vanhoutte P, Betuing S, et al. Huntington's Disease and Striatal Signaling. Front Neuroanat. 2011; 5: 55. doi: 10.3389/fnana.2011.00055 PMID: 22007160
17. Marchina E, Misasi S, Bozzato A, Ferraboli S, Agosti C, Rozzini L, et al. Gene expression profile in fibroblasts of Huntington's disease patients and controls. J Neurol Sci. 2014; 337: 42–46. doi: 10.1016/j.jns.2013.11.014 PMID: 24296361
18. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A 2005; 102: 11023–11028. PMID: 16043692
19. Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A 2007; 104: 14424–14429. PMID: 17724341
20. Lovrecic L, Kastrin A, Kobal J, Pirtosek Z, Krainc D, Peterlin B. Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov Disord. 2009; 24: 2277–2281. doi: 10.1002/mds.22477 PMID: 19844910
21. Chang KH, Chen YC, Wu YR, Lee WF, Chen CM. Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. PLoSOne 2012; 7:e46492. doi: 10.1371/journal.pone.0046492 PMID: 23029535
22. Sanchez-Lopez F, Tasset I, Aguera E, Feijoo M, Fernandez-Bolanos R, Sanchez FM, et al. Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurol Res. 2012; 34: 721–724. doi: 10.1179/1743132812Y.0000000073 PMID: 22889672
23. Krzyszton-Russjan J, Zielonka D, Jackiewicz J, Kusmirek S, Bubko I, Klimberg A, et al. A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: looking for biomarkers. J Bioenerg Biomembr. 2013; 45: 71–85. doi: 10.1007/s10863-012-9479-3 PMID: 23070563
24. Diamanti D, Mori E, Incarnato D, Malusa F, Fondelli C, Magnoni L, et al. Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model. Biomark Res. 2013; 1: 28. doi: 10.1186/2050-7771-1-28 PMID: 24252798

25. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009; 15: 89–100. doi: 10.1016/j.molmed.2009.01.001 PMID: 19230774

26. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276: 24713–24718. PMID: 11319238

27. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 2002; 33: 849–860. PMID: 11906693

28. Song C, Zhang Y, Parsons CG, Liu YF. Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J Biol Chem. 2003; 278: 33364–33369 PMID: 12810713

29. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2006; 21: 392–403. PMID: 16165367

30. Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci. 2007; 27: 3768–3779. PMID: 17409241

31. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003; 39: 227–239. PMID: 12873381

32. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Linlás R, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A 2005; 102: 2602–2607. PMID: 15695335

33. Czeredyś M, Gruszczynska-Biegala J, Schacht T, Methner A, Kuznicki J. Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington’s disease. Front Mol Neurosci. 2013; 6: 42. doi: 10.3389/fnmol.2013.00042 PMID: 24324398

34. Choi KC, An BS, Yang H, Jeung EB. Regulation and molecular mechanisms of calcium transport genes: do they play a role in calcium transport in the uterine endometrium? J Physiol Pharmacol. 2011; 62: 499–504. PMID: 22204796

35. Prasad V, Okunade G, Liu L, Paul RJ, Shull GE. Distinct phenotypes among plasma membrane Ca2+–ATPase knockout mice. Ann N Y Acad Sci. 2007; 1099: 276–286. PMID: 17446488

36. Gora-Kupilas K, Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 2005; 43: 31–39. PMID: 15827888

37. Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, et al. Dose-dependent neuroprotection of VEGF(1(6)(5)) in Huntington’s disease striatum. Mol Ther. 2013; 21: 1862–1875. doi: 10.1038/mt.2013.132 PMID: 23799534

38. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survival via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621–4631. PMID: 11030151

39. Jin K, Mao XO, Batteur SP, McEachron E, Leahy A, Greenberg DA. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience 2001; 108: 351–358. PMID: 11734367

40. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 2000; 97: 10242–10247. PMID: 10963684

41. Oosthuyse B, Moons L, Storksebaum E, Beck H, Nuyens D, Brusselms K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001; 28: 131–138. PMID: 11381259

42. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003; 111: 1843–1851. PMID: 12813020

43. Volm M, Mattern J, Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res. 1999; 19: 1669–1671. PMID: 10470099
45. Zhu Y, Jin K, Mao XO, Greenberg DA. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. Faseb j. 2003; 17: 186–193. PMID:12554697
46. Boyle PJ, Kempers SF, O’Connor AM, Nagy RJ. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333: 1726–1731. PMID:7491135
47. Dantz D, Bewersdorf J, Fruehwald-Schultes B, Kern W, Jelkmann W, Born J, et al. Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocrinol Metab. 2002; 87: 835–840. PMID:11836329
48. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998; 140: 947–959. PMID:9472045
49. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest. 1999; 79: 417–425. PMID:10211994
50. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 1995; 44: 1399–1404. PMID:7589845
51. Nishie A, Ono M, Shono T, Fukushima J, Otsubo M, Onoue H, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999; 5: 1107–1113. PMID:10353745
52. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem. 1990; 265: 18051–18054. PMID:2211680
53. Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci. 2000; 41: 235–239. PMID:8366869
54. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes 1993; 7: 235–239. PMID:8366869
55. Losekoot M, van Belzen MJ, Seneca S, Bauer P, Stenhouse SA, Barton DE, et al. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013; 21: 480–486 doi: 10.1038/ejhg.2012.200 PMID:22990145
56. Livak JK, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods 2001; 25: 402–408. PMID:1184609
57. Lakatta EG. Cardiovascular ageing in health sets the stage for cardiovascular disease. Heart Lung Circ. 2002; 11: 76–91. PMID:16352074
58. Besse S, Assayag P, Delcayre C, Carre F, Cheav SL, Lecarpentier Y, et al. Normal and hypertrophied senescent rat heart: mechanical and molecular characteristics. Am J Physiol. 1993; 265: H183–190. PMID:8342633
59. Guo KK, Ren J. Cardiac overexpression of alcohol dehydrogenase (ADH) alleviates aging-associated cardiomyocyte contractile dysfunction: role of intracellular Ca2+ proteins. Aging Cell 2006; 5: 259–265 PMID:16842498
60. Marian MJ, Mukhopadhyay P, Borchman D, Tang D, Paterson CA. Regulation of sarco/endoplasmic and plasma membrane calcium ATPase gene expression by calcium in cultured human lens epithelial cells. Cell Calcium 2007; 41: 87–95. PMID:16875731
61. DiLeva F, Dori T, Fedrizzi L, Lim D, Carafioli E. The plasma membrane Ca2+ ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys 2008; 476: 65–74. doi: 10.1016/j.abb.2008.02.026 PMID:18328800
62. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yokihara GJ, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. The Journal of Neurosciences 2008; 28(42): 10720–10733. doi: 10.1523/JNEUROSCI.2126-08.2008 PMID:18923047